SPRUCE BIOSCIENCES INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Find out what a historical investment in SPRUCE BIOSCIENCES INC would be worth today using our SPRB stock calculator.
$2.78M
-
0.00%
91.93K
$0.07
$0.06
$0.06
$0.80
$0.06
Ready to start your investing journey with Stake?
Open an accountSPRB FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in SPRB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in SPRB
on Stake
Buy SPRB from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of SPRB from only US$10 with fractional shares
